Brokerages Anticipate Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) Will Post Quarterly Sales of $29.79 Million

Equities analysts expect Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) to post sales of $29.79 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s earnings. The lowest sales estimate is $25.84 million and the highest is $33.73 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share posted sales of $43.09 million during the same quarter last year, which suggests a negative year over year growth rate of 30.9%. The firm is expected to report its next earnings results on Tuesday, March 6th.

According to Zacks, analysts expect that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will report full-year sales of $29.79 million for the current year, with estimates ranging from $165.44 million to $173.32 million. For the next fiscal year, analysts forecast that the firm will post sales of $111.38 million per share, with estimates ranging from $105.03 million to $117.72 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last issued its quarterly earnings data on Wednesday, November 8th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.13. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a net margin of 44.47% and a return on equity of 33.92%. The firm had revenue of $39.68 million for the quarter, compared to the consensus estimate of $38.22 million. During the same quarter in the previous year, the firm earned ($0.08) EPS. The company’s quarterly revenue was up 23.7% compared to the same quarter last year.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a research report on Tuesday. BidaskClub downgraded shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 21st. Finally, Roth Capital set a $14.00 price objective on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share currently has an average rating of “Hold” and a consensus target price of $21.50.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) opened at $9.29 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.53 and a quick ratio of 1.47. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 12-month low of $7.52 and a 12-month high of $12.30. The stock has a market cap of $364.77, a P/E ratio of 4.81 and a beta of 1.34.

In related news, Director Craig R. Stapleton bought 140,000 shares of the company’s stock in a transaction on Friday, December 15th. The shares were bought at an average price of $8.67 per share, with a total value of $1,213,800.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael S. Anderson bought 5,000 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were bought at an average cost of $8.86 per share, for a total transaction of $44,300.00. The disclosure for this purchase can be found here. 5.07% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. grew its position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 2,484.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock worth $121,000 after purchasing an additional 10,532 shares during the last quarter. Nine Chapters Capital Management LLC purchased a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 3rd quarter worth approximately $132,000. Sei Investments Co. grew its position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 29.5% during the 2nd quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock worth $140,000 after purchasing an additional 2,900 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 2nd quarter worth approximately $181,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 3rd quarter worth approximately $184,000. 67.75% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Brokerages Anticipate Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) Will Post Quarterly Sales of $29.79 Million” was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.themarketsdaily.com/2018/01/11/brokerages-anticipate-avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-will-post-quarterly-sales-of-29-79-million.html.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Get a free copy of the Zacks research report on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply